Inclusion Criteria

Criteria:

- Histologically confirmed bronchoalveolar carcinoma (BAC) or adenocarcinoma of the
lung with BAC features:

- Stage IIIB or IV disease:

- Patients with stage IIIB disease must be ineligible for definitive combined
modality treatment with radiotherapy and chemotherapy

- Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by
conventional techniques or >= 10 mm by spiral CT scan:

- Previously irradiated lesions are considered measurable only if lesion
progressed after completion of radiotherapy

- No unstable brain metastases:

- Brain metastases that are stable for ≥ 1 month after completion of prior
radiotherapy, stereotactic surgery, or surgery are allowed

- Performance status:

- ECOG 0-2

- Life expectancy >3 months

- Hepatic:

- Bilirubin normal

- AST and ALT =< 2.5 times upper limit of normal

- Renal:

- Creatinine normal OR creatinine clearance >= 60 mL/min

- Cardiovascular:

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmias

- No more than 1 prior chemotherapy regimen for advanced BAC:

- Prior gefitinib or other known epidermal growth factor receptor (EGFR)
inhibitors are not considered a systemic chemotherapy regimen

- At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

- At least 4 weeks since prior corticosteroids

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception before, during, and for 30 days
after completion of study treatment

- No ongoing or active infection

- No other malignancy within the past 3 years except adequately treated basal cell or
squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated
stage I or II cancer that is in complete remission

- No peripheral neuropathy >= grade 2

- No known hypersensitivity to bortezomib, boron, or mannitol

- No psychiatric illness or social situation that would preclude study compliance

- No other uncontrolled illness

- No concurrent routine granulocyte colony-stimulating factors (e.g., filgrastim
[G-CSF] or sargramostim [GM-CSF])

- At least 2 weeks since prior radiotherapy

- Recovered from prior therapy (alopecia allowed)

- At least 2 weeks since prior EGFR inhibitors

- At least 4 weeks since prior anticonvulsants

- No prior bortezomib

- No concurrent antiretroviral therapy for HIV-positive patients

- No other concurrent investigational agents

- No other concurrent anticancer therapy

- Concurrent bisphosphonates for bone metastases allowed

- Hematopoietic:

- Absolute neutrophil count >= 1,500/mm3

- Platelet count >= 100,000/mm3